News

The U.S. Food and Drug Administration has approved Insightec’s incision-free brain “surgery” technology — Exablate Neuro — for the treatment of motor symptoms in Parkinson’s disease patients. According to the company, the device is indicated to use in patients with moderate-to-severe motor complications, such as tremors, stiffness and uncontrolled, involuntary movement…

Those attending The Michael J. Fox Foundation’s (MJFF) “A Funny Thing Happened on the Way to Cure Parkinson’s” annual fundraiser got to hear from the organization’s founder, Michael J. Fox. Nearly 700 supporters converged on the Jazz at Lincoln Center in New York City recently to celebrate the…

A specific genetic variant, or mutation, that is associated with an increased risk of developing amyotrophic lateral sclerosis (ALS) may also raise a person’s risk of Parkinson’s disease, a study reported. Shared features of both these neurodegenerative disorders include causative processes and “genetic backgrounds,” the researchers noted, suggesting that a mutation affecting…

Jubilee BioTech has developed JUBIwatch, a new device intended to improve patients’ medication adherence — taking medicines at the right time with the right dose. Under development by the startup South Korean company for the past two years, JUBIwatch is a smart watch and medication management platform that uses microneedles…

Clinical trials will begin soon in China to evaluate Luye Pharma’s LY03009, a once-a-month, extended-release investigational therapy to treat people with Parkinson’s disease.  A Phase 1 safety trial is underway in Australia, and the company said…

A team of researchers at Caltech will be looking into the interactions between the brain and the gut in Parkinson’s, in the hope of uncovering how their interaction may affect the disease. Studies are noting abnormalities in the gastrointestinal environment of Parkinson’s patients, and a better understanding of “gut-brain connections”…

Deep brain stimulation (DBS) in adults with early Parkinson’s reduces disease-specific medication use and provides significant cost savings, for up to 15 years, relative to standard care, a study shows. While these savings — just over $100,000 over 15 years — did not outweigh the costs of the surgical…

The launch of a Phase 2 trial into the safety and early efficacy of oral NE3107 in treating Parkinson’s disease patients with motor fluctuations while on levodopa was approved by the U.S. Food and Drug Administration (FDA), BioVie, the therapy’s developer, announced. BioVie plans to initiate patient enrollment for the trial,…

Scientists at the Duke University School of Medicine have received two grants totaling $18 million to investigate how different cells in the brain and in the gut may foster the onset and progression of Parkinson’s disease. The grants from the Aligning Science Across Parkinson’s (ASAP) initiative will fund two…

A neurological surgery professor from Weill Cornell Medicine and his team will use a three-year, $8.9 million research grant to investigate how abnormal protein clumps in the gut can spread to the brain and help drive the early stages of Parkinson’s disease. This grant, from the Aligning Science Across…